

GLOBAL & REGIONAL DAILY

HIGHLIGHTS

November 19, 2020

Global Markets

Investors retained a cautious stance on risk assets early today, as still rising infection rates and tighter Covid-19 measures in several regions around the world, canceled out y-day's more positive Covid-19 vaccine news. Pfizer and BioNTech reported that the final analysis of the Phase 3 trial showed that their vaccine was 95% effective, almost in line with Moderna's vaccine efficacy rate, and plan to submit "within days" an emergency authorization request from the FDA. In FX markets, the EUR/USD retreated to the 1.1830/60 area after failing to break above 1.1900 y-day, while USTs and German Bunds were a tad weaker on the day, but still close to y-day's multi-session highs, on the prevailing view that major CBs are unlikely to shift to a less accommodative monetary policy stance, in spite of encouraging Covid-19 vaccine news.

Greece

The European Commission published yesterday its 8th Enhanced Surveillance Report for Greece. The report is positive overall, acknowledging however the severe downside risks to the outlook due to the pandemic, although funds from the Recovery and Resilience facility could support the economic recovery. On reforms, progress is found particularly in the insolvency framework, the human resources reform of the IAPR, the completion of the Treasury Single Account, the digital transformation of the public sector and the launch of the Target Model for the electricity market. On arrears clearance, the zero arrears target for the end of 2020 in all sectors except for pension claims has been confirmed by the authorities, but remains subject to risks.

CESEE

In the Alert Mechanism Report for 2021, released by the EC yesterday, Bulgaria will not be subject to an in-depth analysis under the Macroeconomic Imbalances Procedure (MIP) after the conclusion in the latest MIP report in February that the country no longer experiences imbalances. In November's Inflation Report, published yesterday, the NBS revised Serbia's projected GDP contraction for 2020 to -1.0% from -1.5% previously, broadly, on the back of faster than expected recovery of investments. All eyes today will be on the European Council's video conference, following the veto imposed by Hungary and Poland on Monday on the EU's EUR1.8trn budget, which is scheduled to take effect on January 1, 2021, with all EU nations being in need of the allocated funds for increased health care demands and economic supportive measures.

Contributing Authors

Paraskevi Petropoulou
Senior Economist
ppetropoulou@eurobank.gr

Anna Dimitriadou
Economic Analyst
andimitriadou@eurobank.gr

Maria Kasola
Economic Analyst
mkasola@eurobank.gr

Research Team



Dr. Tasos Anastasatos | Group Chief Economist
tanastasatos@eurobank.gr | + 30 214 40 59 706



Anna Dimitriadou
Economic Analyst
andimitriadou@eurobank.gr
+ 30 210 37 18 793



Ioannis Gkionis
Senior Economist
igkionis@eurobank.gr
+ 30 214 40 59 707



Dr. Stylianos Gogos
Economic Analyst
sgogos@eurobank.gr
+ 30 210 37 18 733



Maria Kasola
Economic Analyst
mkasola@eurobank.gr
+ 30 210 33 18 708



Olga Kosma
Research Economist
okosma@eurobank.gr
+ 30 210 37 18 728



Paraskevi Petropoulou
Senior Economist
ppetropoulou@eurobank.gr
+ 30 210 37 18 991



Dr. Theodoros Rapanos
Economic Analyst
v-trapanos@eurobank.gr
+ 30 214 40 59 711



Dr. Theodoros Stamatou
Senior Economist
tstamatou@eurobank.gr
+ 30 214 40 59 708



Elia Tsiampaou
Economic Analyst
etsiampaou@eurobank.gr
+ 30 214 40 59 712

Περισσότερες εκδόσεις μας διαθέσιμες στην ηλεκτρονική διεύθυνση που ακολουθεί: <https://www.eurobank.gr/en/group/economic-research>
Εγγραφείτε ηλεκτρονικά, σε: <https://www.eurobank.gr/el/omilos/oikonomikes-analuseis/forma-ekdilosis-endiaferontos>
Ακολουθήστε μας στο twitter: https://twitter.com/Eurobank_Group
Ακολουθήστε μας στο LinkedIn: <https://www.linkedin.com/company/eurobank>

DISCLAIMER

This report has been issued by Eurobank S.A. ("Eurobank") and may not be reproduced in any manner or provided to any other person. Each person that receives a copy by acceptance thereof represents and agrees that it will not distribute or provide it to any other person. This report is not an offer to buy or sell or a solicitation of an offer to buy or sell the securities mentioned herein. Eurobank and others associated with it may have positions in, and may effect transactions in securities of companies mentioned herein and may also perform or seek to perform investment banking services for those companies. The investments discussed in this report may be unsuitable for investors, depending on the specific investment objectives and financial position. The information contained herein is for informative purposes only and has been obtained from sources believed to be reliable but it has not been verified by Eurobank. The opinions expressed herein may not necessarily coincide with those of any member of Eurobank. No representation or warranty (express or implied) is made as to the accuracy, completeness, correctness, timeliness or fairness of the information or opinions herein, all of which are subject to change without notice. No responsibility or liability whatsoever or howsoever arising is accepted in relation to the contents hereof by Eurobank or any of its directors, officers or employees. Any articles, studies, comments etc. reflect solely the views of their author. Any unsigned notes are deemed to have been produced by the editorial team. Any articles, studies, comments etc. that are signed by members of the editorial team express the personal views of their author.

